News of Note—CureVac, Bavarian Nordic and more

non
In this week's of news of note, CureVac's CEO is stepping down. (Pixabay)

Here is some other vaccine news of note for the week.

> Even a flu vaccine 20% effective would avert 21 million infections and save 61,000 lives, as long as about 40% of Americans got their shots, a new study led by Yale University researchers found. HealthDay News article

> CureVac’s founder and CEO Ingmar Hoerr, Ph.D., plans to transition to chairman, handing the reins over to current CBO and U.S. subsidiary CEO Daniel Menichella. Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Bavarian Nordic announced the FDA has granted orphan drug designation to its cancer vaccine BN-Brachyury for the treatment of chordoma. Release

> British firm Scancell raised £8.7 million in a public offering to help advance the development of its cancer vaccines. Labiotech article

The Scripps Research Institute landed a $12 million grant from the Bill & Melinda Gates Foundation to study vaccines that can neutralize many strains of malaria and influenza. Release

> Emergent BioSolutions reported $117.8 million in revenues from the first quarter, hurt by delays in the delivery of BioThrax and ACAM2000. Release

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.